• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
BDSI

BDSI

BioDelivery Sciences International, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD5.59

-0.01 (-0.09%)

Company Profile

CEO

Herm Cukier

IPO Date

2002-07-25

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.60

Prev. Close

$5.59

Day Low

$5.59

Day High

$5.60

52W Low

$2.50

52W High

$5.62

Market Cap

$0.58B

Volume

2.11M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

28.5%

Avg Negative

14.3%

Avg Neutral

57.4%

News Feed

BioDelivery Sciences: Yet Another Buying Opportunity

Seeking Alpha·8/27/2021·↓ negative

BioDelivery Sciences International (BDSI) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Investment Research·8/10/2021·↑ positive

BioDelivery Sciences International, Inc.'s (BDSI) CEO Jeff Bailey on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/4/2021·↓ negative

BioDelivery Sciences Reports Mixed Q2 Earnings, Sees FY21 Belbuca Sales At Lower End Of Guidance Range

Benzinga·8/4/2021·↑ positive

BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine

GlobeNewsWire·8/4/2021·↑ positive

This Undervalued Biotech Penny Stock Could Soon Double

The Motley Fool·7/13/2021·↑ positive

BioDelivery Sciences: Clinic-To-Market Transition Problem

Seeking Alpha·5/28/2021·↑ positive

BioDelivery Sciences International, Inc. (BDSI) CEO Jeffrey Bailey on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/6/2021·↓ negative

BioDelivery Sciences International (BDSI) Misses Q1 Earnings Estimates

Zacks Investment Research·5/6/2021·↑ positive

BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research·4/29/2021·↑ positive